Promising Developments in Alumis Inc.’s Clinical Programs Support Buy Rating

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ALMS stock, giving a Buy rating on March 3.

Thomas Smith’s rating is based on several promising developments in Alumis Inc.’s clinical programs. The company has shown positive progress with its lead program, ESK-001, a TYK2 inhibitor for psoriasis. The timing for the release of Phase 3 trial data has been narrowed to the first quarter of 2026, indicating strong enrollment trends and effective clinical execution. Additionally, the acceptance of long-term data for ESK-001 as a late-breaking presentation at a major dermatology conference suggests significant interest and confidence in its efficacy.
Furthermore, Alumis Inc.’s CNS-penetrant TYK2 inhibitor, A-005, has demonstrated the ability to cross the blood-brain barrier effectively, with favorable pharmacokinetics and no serious adverse events reported. This reinforces the potential of A-005 to address inflammation in the central nervous system, a challenging therapeutic area. Overall, the compelling clinical profiles of both ESK-001 and A-005 support the Buy rating, as they offer potential best-in-class treatments in their respective areas.

In another report released on March 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $19.00 price target.